Y
Ying Yuan
Researcher at Discovery Institute
Publications - 13
Citations - 5204
Ying Yuan is an academic researcher from Discovery Institute. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 3, co-authored 6 publications receiving 4841 citations. Previous affiliations of Ying Yuan include Novartis.
Papers
More filters
Journal ArticleDOI
Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen.
Charles K. Stover,X. Q. Pham,A. L. Erwin,S. D. Mizoguchi,Paul Warrener,Mark J. Hickey,Fiona S. L. Brinkman,W. O. Hufnagle,D. J. Kowalik,Lagrou Mj,R. L. Garber,L. Goltry,E. Tolentino,S. Westbrock-Wadman,Ying Yuan,L. L. Brody,S. N. Coulter,K. R. Folger,Arnold Kas,K. Larbig,R. Lim,Kelly D. Smith,David H. Spencer,Gane Ka-Shu Wong,Z. Wu,Ian T. Paulsen,Ian T. Paulsen,Jonathan Reizer,Milton H. Saier,Robert E. W. Hancock,Stephen Lory,Maynard V. Olson +31 more
TL;DR: It is proposed that the size and complexity of the P. aeruginosa genome reflect an evolutionary adaptation permitting it to thrive in diverse environments and resist the effects of a variety of antimicrobial substances.
Journal ArticleDOI
A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis.
C. Kendall Stover,Paul Warrener,Donald R. VanDevanter,David R. Sherman,Taraq M. Arain,Michael H. Langhorne,Scott Anderson,J. Andrew Towell,Ying Yuan,David N. McMurray,Barry N. Kreiswirth,Clifton E. Barry,William R. Baker +12 more
TL;DR: It is concluded that nitroimidazopyrans offer the practical qualities of a small molecule with the potential for the treatment of tuberculosis and bactericidal activity against both replicating and static M. tuberculosis.
Journal ArticleDOI
The Tuberculosis Drug Accelerator at year 10: what have we learned?
Bree B. Aldridge,David Barros-Aguirre,Clifton E. Barry,Robert H. Bates,Steven Joseph Berthel,Helena I. Boshoff,Kelly Chibale,Xin-Jie Chu,Christopher B. Cooper,Véronique Dartois,Ken Duncan,Nader Fotouhi,Fabian Gusovsky,Philip Arthur Hipskind,Dale J. Kempf,Joël Lelièvre,Anne J. Lenaerts,Case W. McNamara,Valerie Mizrahi,Carl Nathan,David B. Olsen,Tanya Parish,H. Michael Petrassi,Alexander Pym,Kyu Y. Rhee,Gregory T. Robertson,Jeremy M. Rock,Eric J. Rubin,Betsy Russell,David G. Russell,James C. Sacchettini,Dirk Schnappinger,Michael R. Schrimpf,Anna Upton,Peter Warner,Paul G. Wyatt,Ying Yuan +36 more
TL;DR: The Tuberculosis Drug Accelerator (TADA) as discussed by the authors is an experiment designed to facilitate collaboration in tuberculosis drug discovery by breaking down barriers among competing labs and institutions, and has reached a 10-year landmark.
Journal ArticleDOI
Design, Synthesis, and Characterization of TNP-2198, a Dual-Targeted Rifamycin-Nitroimidazole Conjugate with Potent Activity against Microaerophilic and Anaerobic Bacterial Pathogens
Zhen Ma,Shijie He,Ying Yuan,Zhijun Zhuang,Yu Liu,Huan-huan Wang,Xiangyi Xu,Charles Z. Ding,Vadim Molodtsov,Wei Lin,Gregory T. Robertson,William A. Weiss,Mark Pulse,Phung Nguyen,Leonard R. Duncan,Timothy B Doyle,Richard H. Ebright,A. Simon Lynch +17 more
TL;DR: TNP-2198 as mentioned in this paper is a dual-targeted antibacterial agent for the treatment of microaerophilic and anaerobic bacterial infections, which exhibits higher activity than a 1:1 molar mixture of the parent drugs and exhibits activity against strains resistant to both rifamycins and nitroimidazoles.
Journal ArticleDOI
In vitro activity of TNP-2092 against periprosthetic joint infection-associated staphylococci.
TL;DR: Results of this study show that TNP-2092 has promising in vitro activity against PJI-associated staphylococci.